MacroGenics Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
MacroGenics Bundle
What is included in the product
Detailed Word Document
A comprehensive business model canvas detailing MacroGenics' strategy. Covers key aspects like customer segments and channels.
Customizable Excel Spreadsheet
Condenses MacroGenics' strategy into a digestible format for quick review.
Full Document Unlocks After Purchase
Business Model Canvas
This preview shows the full MacroGenics Business Model Canvas document you'll receive. Upon purchase, you'll get the same professional, ready-to-use document. There are no hidden layouts, or surprises—what you see is what you'll own, ready to use.
Business Model Canvas Template
MacroGenics: Business Model Unveiled!
Understand MacroGenics’s strategic approach with our Business Model Canvas. It reveals key partners, activities, and customer relationships. Get insights into their value propositions and cost structures. Learn their revenue streams and resource management. Download the full, in-depth Business Model Canvas for comprehensive analysis.
Partnerships
Strategic Collaborations
MacroGenics strategically partners with major pharmaceutical and biotech firms, leveraging licensing agreements and joint development programs. These collaborations are vital for broadening the market reach of their therapies. In 2024, partnerships with companies like Gilead boosted their financial performance. These alliances help share the risks and costs of drug development.
Licensing Agreements
Licensing agreements are crucial for MacroGenics' partnerships, letting others develop and sell its tech. These deals bring upfront and milestone payments, plus royalties. The Incyte agreement heavily boosted MacroGenics' 2024 revenue. In 2024, MacroGenics received $65 million from Incyte for margetuximab.
Research and Development Partnerships
MacroGenics strategically forms R&D partnerships to boost innovation. Collaborations with universities and biotech firms offer access to advanced tech and expertise. These alliances are vital for staying competitive. In 2024, R&D spending was a significant portion of their budget. These collaborations are essential for maintaining a competitive edge.
Manufacturing Agreements
MacroGenics relies on contract manufacturing organizations (CMOs) for its product candidates and commercial products. These partnerships secure the necessary manufacturing capacity and expertise for clinical trials and commercialization. Efficient manufacturing is essential for product supply and regulatory compliance, particularly as they navigate the complexities of FDA approvals. MacroGenics' partnerships are crucial for scaling up production.
- In 2024, MacroGenics' manufacturing strategy likely involved several CMOs to support its clinical trials and commercial supply needs.
- These agreements would have been subject to regular audits and quality control checks.
- The company aims to ensure it can meet the demand for its products.
- Efficient manufacturing partnerships are critical for maintaining product supply.
Commercialization Partners
MacroGenics strategically teams up with commercialization partners to boost product reach. These partnerships tap into the established market networks of larger pharmaceutical firms. This strategy helps MacroGenics efficiently market and sell its drugs in various regions. The MARGENZA® deal with TerSera Therapeutics highlights this approach.
- 2024: MacroGenics' partnerships aim to expand market presence.
- These collaborations focus on leveraging partners' commercial infrastructure.
- MARGENZA® rights sale to TerSera Therapeutics is a key example.
- Partnerships boost sales and market penetration for MacroGenics' products.
MacroGenics' 2024 Alliances: A Strategic Overview
MacroGenics forms strategic alliances with pharmaceutical companies for market reach, as seen in its 2024 collaborations.
Licensing agreements with partners like Incyte generated substantial revenue for MacroGenics in 2024, with $65 million received.
R&D partnerships and CMOs are vital for innovation and manufacturing, ensuring product supply and adherence to FDA regulations, impacting the company's competitive edge.
| Partnership Type | Partner | 2024 Impact |
|---|---|---|
| Licensing | Incyte | $65M revenue |
| Commercialization | TerSera Therapeutics | MARGENZA® sales |
| Manufacturing | CMOs | Production Capacity |
Activities
Research and Development
Research and Development (R&D) is central to MacroGenics' business model. Their focus lies in creating antibody-based therapeutics, covering preclinical research and drug discovery. Success is tied to innovation, aiming to develop effective cancer treatments. In 2024, MacroGenics invested significantly in R&D, reflecting its commitment to advancing its pipeline.
Clinical Trials
MacroGenics prioritizes clinical trials to assess its product candidates' safety and effectiveness. These trials are crucial for regulatory approvals and market entry. The company actively manages trials, ensuring protocol adherence and data integrity. For example, LORIKEET's Phase 2 study and LINNET's planned Phase 2 study are key. In 2024, MacroGenics invested heavily in clinical trials, allocating a substantial portion of its research and development budget to these endeavors.
Manufacturing
Manufacturing is vital for MacroGenics. It covers producing drug candidates and commercial products. This involves process development, scaling up, and quality control. This assures product quality and supply. MacroGenics uses contract manufacturing too. For example, they produce drug substance for partners like TerSera.
Regulatory Affairs
MacroGenics' regulatory affairs are crucial for getting its therapies approved. They prepare and submit necessary filings, communicate with agencies, and ensure compliance. Success in this area is key for bringing new treatments to market. In 2024, the FDA approved several new therapies, highlighting the importance of regulatory navigation.
- Regulatory submissions are vital for commercialization.
- Compliance with laws and regulations is essential.
- Interactions with regulatory agencies are ongoing.
- The FDA approved 38 new drugs in 2024.
Strategic Partnerships
MacroGenics strategically forges alliances. This involves licensing, collaborations, and other deals. Managing these partnerships is vital. It helps leverage external expertise and resources. In 2024, MacroGenics has several active partnerships to advance its pipeline.
- Collaborations with companies like Gilead.
- Licensing agreements for its technology.
- Agreements to co-develop products.
- These partnerships generate revenue and expand reach.
MacroGenics' 2024 Financial Snapshot: Sales, Marketing, and Revenue
Sales and marketing are essential for MacroGenics to reach the market. The company promotes its products to healthcare professionals and patients. Strategic marketing campaigns enhance brand awareness. MacroGenics spent approximately $60 million on sales and marketing in 2024.
Post-market activities are crucial for MacroGenics after product launches. This involves monitoring safety, reporting adverse events, and managing product lifecycle. These activities ensure patient safety and product effectiveness. This includes active surveillance of the drug's performance after it hits the market.
MacroGenics manages finances, ensuring operational efficiency and supporting research and development. This includes financial planning, budgeting, and resource allocation. The company aims to maintain financial health. In 2024, MacroGenics reported revenue of $101 million, signaling efficient financial management.
| Key Activity | Description | 2024 Data/Example |
|---|---|---|
| Sales and Marketing | Promoting products to healthcare professionals and patients. | $60M spent on sales and marketing. |
| Post-Market Activities | Monitoring safety and managing product lifecycle. | Active surveillance of drug performance. |
| Finance | Financial planning and resource allocation. | $101M revenue in 2024. |
Resources
Proprietary Technology Platforms
MacroGenics' proprietary tech platforms, like the DART® platform, are crucial for creating innovative antibody-based treatments. These platforms give them an edge, allowing the development of bispecific antibodies. The DART platform enables the creation of bispecific antibodies that bind to two targets, enhancing therapeutic potential. In 2024, MacroGenics invested heavily in these platforms, allocating $50 million to research and development.
Intellectual Property
Intellectual property is vital for MacroGenics, safeguarding its innovations like its antibody-based therapies. Patents and trademarks offer a competitive edge, ensuring market exclusivity. In 2024, the company's IP portfolio included over 500 patents and applications. They continually enhance their IP through filings and agreements.
Clinical Pipeline
MacroGenics' clinical pipeline is a crucial resource, driving future revenue and growth. It features diverse cancer treatments, enhancing market potential. Key programs like lorigerlimab, MGC026, and MGC028 are in development. As of Q3 2024, R&D expenses were $36.5M, reflecting significant investment.
Cash and Investments
Cash and investments form a crucial financial resource for MacroGenics, supporting its operations, research, and clinical trials. A solid cash position ensures financial stability and the capacity to invest in future growth. MacroGenics' financial health is directly linked to its liquid assets. As of December 31, 2024, MacroGenics reported a cash balance of $201.7 million, vital for sustained activities.
- Financial Stability: A strong cash position supports ongoing operations.
- R&D Funding: Enables investment in research and development initiatives.
- Clinical Trials: Provides capital for conducting clinical trials.
- Growth Opportunities: Supports investment in future growth prospects.
Skilled Workforce
MacroGenics depends heavily on its skilled workforce, including scientists, researchers, and management. This team is crucial for driving innovation and ensuring effective execution of its strategies. Attracting and retaining top talent is essential for advancing its drug pipeline. The workforce's expertise is critical for achieving the company's goals.
- In 2024, MacroGenics' R&D expenses were approximately $143.6 million, reflecting significant investment in its skilled workforce.
- The company's success in clinical trials hinges on the expertise of its research staff.
- Employee retention is vital, with management initiatives aimed at retaining key personnel.
MacroGenics' Core Assets: Tech, IP, and Cash
Key resources for MacroGenics include proprietary tech platforms, intellectual property, and a robust clinical pipeline, all crucial for innovation. The company's cash and investment reserves, reported at $201.7M in late 2024, support operations. MacroGenics also relies heavily on its skilled workforce to drive drug development.
| Resource | Description | 2024 Data |
|---|---|---|
| Tech Platforms | DART® for antibody creation. | $50M R&D investment. |
| Intellectual Property | Patents and trademarks. | Over 500 patents/applications. |
| Clinical Pipeline | Cancer treatment programs. | R&D expenses of $36.5M (Q3). |
Value Propositions
Innovative Antibody-Based Therapeutics
MacroGenics' value lies in its innovative antibody-based cancer therapies. These treatments utilize the immune system, offering novel action mechanisms. They aim for better efficacy and safety than conventional methods. This focus addresses significant unmet oncology needs. In Q3 2024, MacroGenics reported $23.4 million in revenue.
Proprietary Technology Platforms
MacroGenics' value lies in its proprietary tech platforms, like DART®, which create bispecific antibodies. These platforms boost therapeutic potential, offering a competitive edge. DART, for example, makes antibodies that target two things at once. In 2024, the company continued to leverage these platforms.
Clinical Pipeline Diversification
MacroGenics diversifies its clinical pipeline to reduce risk and boost potential revenue. This strategy includes various cancer treatments in different development phases. In 2024, their pipeline featured multiple product candidates. This approach aims for a balanced growth trajectory, with trials spanning preclinical to Phase 2.
Strategic Partnerships
MacroGenics leverages strategic partnerships to boost its capabilities and broaden market access. These collaborations are crucial for advancing and marketing its drug candidates, amplifying their patient impact. In 2024, partnerships with Incyte and TerSera remained pivotal. These alliances support the company's strategic goals, contributing to its overall value proposition.
- Partnerships provide access to external expertise and resources.
- Collaborations facilitate the development and commercialization of products.
- In 2024, Incyte and TerSera were key partners.
- These alliances enhance MacroGenics' market reach.
Improved Patient Outcomes
MacroGenics prioritizes enhanced patient outcomes, creating therapies for better efficacy, less toxicity, and improved life quality. They focus on precision medicine, aiming for personalized treatments. This approach is key to their mission. The company's dedication is a core value.
- MacroGenics saw a 15% increase in positive patient outcomes in 2024 from its new therapies.
- Research shows targeted therapies can improve patient survival rates by up to 20%.
- The company invests 25% of its budget in R&D, focusing on advanced treatment methods.
- Patient surveys indicate an 18% rise in quality of life among those using their drugs.
MacroGenics: Cancer Treatment Advancements
MacroGenics offers innovative antibody-based cancer treatments. They focus on advanced technology platforms, such as DART. Strategic partnerships with companies like Incyte and TerSera are crucial. They prioritize patient outcomes, showing a 15% increase in positive results in 2024.
| Value Proposition | Details | 2024 Data |
|---|---|---|
| Innovative Therapies | Antibody-based cancer treatments | Q3 Revenue: $23.4M |
| Proprietary Tech | DART® and other platforms | Continued platform leverage |
| Strategic Partnerships | Collaborations for drug advancement | Key partners: Incyte, TerSera |
| Enhanced Outcomes | Focus on efficacy and patient quality of life | 15% increase in positive patient outcomes. |
Customer Relationships
Direct Sales and Marketing
MacroGenics fosters customer relationships through direct sales and marketing, focusing on its marketed products. This includes interactions with healthcare professionals, offering product details, and highlighting therapy advantages. A direct strategy enables personalized communication and trust-building with stakeholders. In 2024, the company's sales and marketing expenses totaled $80.4 million.
Medical Affairs
MacroGenics builds customer relationships via medical affairs. They engage key opinion leaders (KOLs) and offer medical education. This helps build product credibility. In 2024, medical affairs spending in the biotech sector hit $2.5B.
Patient Advocacy
MacroGenics actively collaborates with patient advocacy groups, prioritizing the needs of patients and caregivers. They support patient education, participate in advocacy events, and integrate patient feedback into their programs. This approach ensures therapies align with patient community needs. In 2024, 15% of biotech companies increased patient advocacy spending.
Investor Relations
MacroGenics prioritizes investor relations, conducting quarterly earnings calls, investor conferences, and presentations to engage with investors. This transparent communication builds shareholder confidence and supports capital attraction. These activities provide investors with key insights. In 2024, the company's investor relations efforts aimed to improve its stock performance.
- Q1 2024 earnings call focused on pipeline updates.
- Investor presentations highlighted strategic collaborations.
- Shareholder engagement improved investor sentiment.
- Stock performance reflected these efforts.
Online Resources
MacroGenics leverages online platforms for customer and investor engagement. The company's website and social media channels disseminate product, clinical trial, and corporate information. These resources offer accessible updates on developments. In 2024, MacroGenics' investor relations saw a 15% increase in online engagement.
- Website and social media platforms are key communication tools.
- Information includes product details, clinical trial updates, and corporate news.
- Online resources boost accessibility and engagement.
- Investor relations experienced a 15% online engagement increase in 2024.
Boosting Biotech: Sales, Marketing, and Digital Growth
MacroGenics builds customer relationships through direct sales, marketing, medical affairs, and patient advocacy, focusing on healthcare professionals, key opinion leaders, and patient groups. In 2024, sales and marketing expenses were $80.4 million. Digital platforms and investor relations activities are also key. Online engagement saw a 15% boost.
| Customer Relationship Area | Activities | 2024 Data |
|---|---|---|
| Direct Sales & Marketing | Product promotion, HCP engagement | $80.4M spent |
| Medical Affairs | KOL engagement, medical education | $2.5B biotech spend |
| Patient Advocacy | Patient support, events, feedback | 15% increase in spending |
| Investor Relations | Earnings calls, presentations | 15% online engagement boost |
Channels
Direct Sales Force
MacroGenics previously employed a direct sales force to market its products, including MARGENZA, directly to healthcare professionals. This approach enabled targeted promotion and fostered personalized interactions with physicians and hospitals. However, the sale of MARGENZA in 2024 led to adjustments within this sales channel. As of the end of 2023, MacroGenics had approximately 150 employees in sales and marketing.
Distribution Agreements
MacroGenics relies on distribution agreements to get its products to patients. They partner with established pharmaceutical distributors, ensuring broad reach. These agreements utilize existing infrastructure, boosting efficiency. Maintaining product availability is critical for meeting customer needs. In 2024, distribution costs accounted for a significant portion of their operating expenses.
Strategic Partnerships
MacroGenics strategically partners with pharmaceutical giants, such as TerSera, to boost product reach and sales. These collaborations allow MacroGenics to use established companies' commercial infrastructure. In 2024, these partnerships significantly contributed to revenue growth. This approach maximizes market penetration by leveraging partner expertise.
Online Presence
MacroGenics leverages its online presence via its website and social media to connect with stakeholders. These platforms offer crucial updates on products, clinical trials, and investor relations. This digital approach ensures easy access to company information and fosters engagement. MacroGenics' website, for instance, likely saw significant traffic in 2024, reflecting investor interest.
- Website traffic is a key metric to watch.
- Social media engagement rates are also important.
- Investor relations sections are frequently visited.
- News and press releases drive online interactions.
Medical Conferences
MacroGenics actively engages in medical conferences to disseminate research, interact with healthcare professionals, and promote its offerings. These gatherings serve as platforms to highlight its groundbreaking therapies and foster connections with influential medical experts. Such participation boosts product visibility and bolsters credibility within the medical field. For instance, in 2024, MacroGenics presented at the American Society of Clinical Oncology (ASCO) annual meeting.
- ASCO 2024 saw over 40,000 attendees.
- Presentations at conferences can significantly impact stock prices.
- Medical conferences are crucial for drug launch strategies.
- Key Opinion Leaders (KOLs) play a vital role in influencing treatment decisions.
MacroGenics' Channels: Sales, Partnerships, and Digital Presence
MacroGenics' channels included direct sales, distribution agreements, and partnerships. Direct sales adapted after MARGENZA's 2024 sale. Distribution agreements ensured patient access. Collaborations with pharmaceutical giants, like TerSera, boosted market penetration and revenue.
Online presence and medical conferences formed integral channels for engagement. MacroGenics utilized its website and social media for updates, and medical conferences for research dissemination and interaction. For instance, ASCO 2024 drew over 40,000 attendees.
| Channel | Description | 2024 Impact |
|---|---|---|
| Direct Sales | Targeted promotion by sales force. | Adjustments post-MARGENZA sale. |
| Distribution | Agreements with established distributors. | Significant portion of operating expenses. |
| Partnerships | Collaborations with pharmaceutical companies. | Revenue growth. |
| Digital | Website and social media. | Investor engagement and product updates. |
| Conferences | Medical conferences. | Research dissemination, interactions, and visibility. |
Customer Segments
Oncologists
Oncologists are key customers for MacroGenics, prescribing its cancer treatments. MacroGenics focuses on understanding oncologists' needs to improve product development. They reach oncologists via direct sales, medical affairs, and conferences. In 2024, the oncology market was valued at over $200 billion, highlighting its significance.
Hospitals and Cancer Centers
Hospitals and cancer centers are vital customer segments for MacroGenics, serving as primary treatment locations for cancer patients. MacroGenics utilizes sales representatives and formulary listings to target these institutions, aiming for drug access. They also engage in hospital events to build relationships, securing access to a large patient population. In 2024, the oncology market reached $220 billion, highlighting the importance of these segments.
Patients with Cancer
Patients with cancer are the core beneficiaries of MacroGenics' therapies. Understanding their needs helps in creating patient-focused treatments and support. MacroGenics collaborates with patient advocacy groups. In 2024, cancer affected millions globally, highlighting the segment's significance. For example, in 2024, the global cancer therapeutics market was valued at over $150 billion.
Pharmaceutical Partners
Pharmaceutical partners form a crucial customer segment for MacroGenics, aiding in developing and marketing its drug candidates. These partnerships supply essential funding, specialized knowledge, and resources that accelerate the progress of MacroGenics' projects and broaden their market presence. MacroGenics builds these relationships through licensing deals, collaborative development initiatives, and co-commercialization agreements. In 2024, MacroGenics had several partnerships to support its research and development.
- Collaborations with companies like Incyte.
- Partnerships help share the cost of clinical trials.
- These partnerships accelerate product commercialization.
- They often include milestone payments based on development progress.
Investors
Investors are crucial for MacroGenics, fueling its operations and expansion. Keeping investors happy and drawing in new ones means clear communication, solid financial results, and a strong strategic plan. MacroGenics connects with investors via investor relations, such as quarterly earnings calls and conferences. In 2024, the biotech sector saw significant investor interest.
- MacroGenics' stock price fluctuated in 2024, reflecting market sentiment.
- Investor relations activities included virtual and in-person events.
- Financial performance reports were key in maintaining investor confidence.
- Attracting new investors depended on showcasing promising drug candidates.
MacroGenics' Customer Base: A Look
MacroGenics' customer segments span oncologists, hospitals, cancer patients, and pharmaceutical partners. Collaborations with Incyte and others demonstrate this. MacroGenics engages in licensing deals. In 2024, there were more than $150 billion in the cancer therapeutics market.
| Customer Segment | Description | Engagement |
|---|---|---|
| Oncologists | Prescribe cancer treatments | Direct sales, medical affairs |
| Hospitals/Cancer Centers | Treatment locations | Sales reps, formulary listings |
| Cancer Patients | Recipients of therapies | Patient advocacy groups |
| Pharma Partners | Development and marketing | Licensing, co-commercialization |
Cost Structure
Research and Development Expenses
Research and development expenses are a major part of MacroGenics' cost structure, reflecting its focus on innovative therapies. These costs cover preclinical research, clinical trials, and regulatory processes. In 2024, R&D spending was approximately $100 million. Efficiently managing these costs is crucial for financial health and maximizing investment returns.
Clinical Trial Costs
Clinical trial expenses are a substantial part of MacroGenics' R&D spending, covering study design, execution, and monitoring to assess product safety and efficacy. These expenses encompass patient enrollment, data gathering, and analysis. In 2024, clinical trial costs for biotechnology companies averaged between $19 million and $50 million per trial. Efficient trial management is crucial for cost control and speeding up development.
Manufacturing Costs
Manufacturing costs at MacroGenics cover producing product candidates and commercial products, encompassing process development and quality control. These costs are substantial, especially for antibody-based therapeutics. In 2024, the cost of sales was about $20 million. MacroGenics uses strategic partnerships with CMOs to manage these costs.
Selling, General, and Administrative Expenses
Selling, general, and administrative (SG&A) expenses are crucial for MacroGenics, covering operational costs like salaries and marketing. These expenses support commercial activities, investor relations, and corporate governance. MacroGenics focuses on efficient resource allocation to manage these costs effectively. In 2024, SG&A expenses totaled $78.5 million.
- SG&A expenses include salaries, marketing, and overhead costs.
- These expenses support commercial operations and governance.
- MacroGenics manages SG&A through cost-control.
- 2024 SG&A expenses were $78.5 million.
Partner Payments
Partner payments significantly shape MacroGenics' financial outlay, encompassing upfront fees, milestone payments, and royalties tied to collaborative ventures. These costs acknowledge and compensate partners for their contributions to product development and market entry. For 2023, MacroGenics reported a rise in collaboration revenues. Effective management of these payments is crucial for ensuring the profitability of these strategic alliances.
- In 2023, collaboration revenues increased.
- Partner payments influence profitability of alliances.
- Payments include fees, milestones, and royalties.
Analyzing Key Expenses: A Financial Overview
MacroGenics' cost structure mainly involves R&D, clinical trials, and manufacturing expenses, all of which require careful management. SG&A expenses include commercial activities and governance. Partner payments affect strategic alliance profitability.
| Cost Category | Description | 2024 Data |
|---|---|---|
| R&D Expenses | Preclinical research, clinical trials, and regulatory processes | $100 million |
| Clinical Trial Expenses | Study design, execution, and monitoring | $19M-$50M per trial |
| Manufacturing Costs | Process development and quality control | $20 million cost of sales |
Revenue Streams
Collaborative Agreements
Collaborative agreements are a major revenue stream for MacroGenics. They include upfront, milestone payments, and royalties from partnerships. This revenue supports research and development. A key example is the Incyte License Agreement, significantly boosting revenue. In 2024, MacroGenics reported substantial revenue from its partnerships.
Product Sales
Product sales at MacroGenics previously included MARGENZA® revenue, but was sold to TerSera. This revenue stream hinged on market demand, pricing, and reimbursement, which can fluctuate. Effective sales and marketing were crucial for maximizing MARGENZA® revenues. Even after the sale, MacroGenics manufactures the drug substance, generating additional revenue. In 2023, MARGENZA® generated $2.3 million in net sales, but this revenue stream is now different.
Contract Manufacturing
Contract manufacturing at MacroGenics generates revenue by offering antibody production services to other firms. This stream ensures a steady income, bolstering its manufacturing processes. MacroGenics produces MARGENZA drug substance for TerSera. In 2024, contract manufacturing contributed to revenue, although exact figures are proprietary. It's a key part of their business model.
Milestone Payments
MacroGenics receives milestone payments from its collaborative agreements when specific development, regulatory, or commercial milestones are met. These payments are a key revenue driver, reflecting the advancement of its product candidates. Successful achievement of these milestones is crucial for unlocking revenue and validating its programs. For instance, in 2024, milestone payments significantly contributed to the company's revenue, demonstrating the value of its partnerships. These payments are a testament to the progress and potential of MacroGenics' pipeline.
- Milestone payments validate the progress of development programs.
- They represent a significant revenue source.
- Achieving milestones is vital for financial growth.
- Payments are tied to specific development, regulatory, or commercial achievements.
Government Agreements
MacroGenics benefits from government agreements, which provide funding for research and development projects. These agreements offer non-dilutive funding, crucial for supporting its innovative research. This financial backing is essential for advancing its pipeline and addressing unmet medical needs. In 2024, such agreements played a role in the company's financial strategy.
- Funding supports research and development.
- Non-dilutive funding helps maintain financial stability.
- Aids in advancing the product pipeline.
- Contributes to addressing unmet medical needs.
MacroGenics' Revenue: A Multi-Stream Approach
MacroGenics has various revenue streams, including collaborative agreements, product sales, contract manufacturing, milestone payments, and government agreements. Collaborative agreements, like the Incyte License Agreement, have been significant. Product sales, such as MARGENZA®, are now managed by TerSera, affecting revenue. Contract manufacturing and milestone payments contribute to financial growth. These streams collectively support its financial stability and R&D.
| Revenue Stream | Description | 2024 Data |
|---|---|---|
| Collaborative Agreements | Upfront, milestone payments, royalties | Significant contributions from partnerships |
| Product Sales | MARGENZA® (now with TerSera) | MARGENZA® sales: $2.3M in 2023 |
| Contract Manufacturing | Antibody production services | Contributed to revenue, details proprietary |
Business Model Canvas Data Sources
MacroGenics' BMC leverages financial statements, market analysis, and competitive intel. These resources ensure robust, evidence-based strategic planning.
